Natera’s Prospera Test to Monitor Eledon’s Phase 3 Kidney Transplant Trial — Natera, Inc.

Event summary

Natera’s Prospera kidney transplant assessment test will be the exclusive dd-cfDNA monitoring assay in Eledon’s Phase 3 trial of tegoprubart, an investigational therapy for organ rejection.
The trial aims to enroll approximately 600 kidney transplant recipients across over 100 global centers, set to initiate in late 2026.
Prospera’s two-threshold algorithm will monitor allograft health longitudinally, detecting early signs of rejection.
This marks the first large-scale therapeutic clinical trial incorporating Prospera as a longitudinal surveillance tool.

The big picture

This partnership underscores the growing emphasis on non-invasive, precision monitoring in organ transplantation. The trial’s success could validate Prospera as a critical tool for optimizing immunosuppression therapies, addressing long-standing challenges in transplant care. Eledon’s tegoprubart represents a novel approach to reducing the burden of current treatments, aligning with broader industry trends toward targeted immune modulation.

What we're watching

Clinical Validation: Whether Prospera’s longitudinal monitoring can demonstrate its value in a large-scale Phase 3 trial, potentially setting a new standard for allograft health surveillance.
Therapeutic Impact: How tegoprubart performs against current immunosuppression regimens and whether it can reduce toxicities while improving graft protection.
Market Adoption: The pace at which Prospera’s integration into clinical trials could accelerate its adoption as a routine molecular surveillance tool in transplantation.